Australia's most trusted
source of pharma news
Wednesday, 04 February 2026
Posted 4 February 2026 AM
A massive 17 pharmas have filed new indications for their medicines in Australia with Novartis looking to expand two of its drugs.
Novartis has an updated version of its spinal muscular atrophy gene therapy Zolgenmsa, which is administered via spinal injection rather than an intravenous infusion for older children.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.